ATXS · CIK 0001454789
What Astria Therapeutics, Inc. told the SEC could break it.
Astria's disclosures lean heavily on a single-source supply chain it doesn't control. It owns no manufacturing and relies on single-source contract manufacturers for the antibodies, drug substance and drug product behind its lead candidates navenibart and STAR-0310, plus their labeling, packing and drug-device combinations — and those manufacturers in turn depend on single-source suppliers for certain raw materials and components, so a supplier loss, capacity constraint or trade barrier could halt supply and delay development. As a clinical-stage company it has generated no product revenue and may need additional financing sooner than planned, while its candidates still face FDA marketing approval and exposure to Medicare and other reimbursement reductions.
4 self-disclosed vulnerabilities, pulled from its own filings, each in the company’s words, with the source. This is the risk register almost nobody reads.
In its own words
What could break it.
Sole-source dependency
- single-source CMs for navenibart/STAR-0310 antibodies, fill-finish and drug-device comboshigh
Astria owns no manufacturing and relies on single-source third-party contract manufacturers for the antibodies, drug substance and drug product for navenibart and STAR-0310, plus labeling/packing and its drug-device combinations — with limited qualified replacements, a supplier loss could halt supply.
“We generally rely on single source third-party manufacturers and suppliers for the antibodies used to make navenibart and STAR-0310 drug substance and drug product, to label and pack navenibart, and to supply our drug device combinations of navenibart, and we expect to continue to do so to meet our nonclinical, clinical”
SEC filing →As of 2025
Liquidity & debt
- no product revenue; dependence on additional financingmedium
Astria has generated no product-sales revenue as a clinical-stage company and may need additional financing to fund long-term operations sooner than planned, leaving it dependent on capital-market access to advance navenibart and STAR-0310.
“As of December 31, 2024, we have not generated any revenue from product sales.”
SEC filing →As of 2025
Other disclosures
- CMs depend on single-source raw-material/component suppliers; trade-barrier supply disruptionmedium
Astria's contract manufacturers in turn rely on single-source suppliers for certain raw materials and drug/device components; cessation, capacity constraints, trade barriers or import/export controls could leave Astria unable to obtain materials and delay development.
“We may be unable to obtain raw materials or drug or device components for an indeterminate period of time if any of our third-party suppliers or manufacturers were to cease or interrupt production or otherwise fail to supply these materials or components to us for any reason, including due to trade barriers, import/export con”
SEC filing →As of 2025
Regulatory & policy
- FDA BLA/NDA approval process and Medicare drug-pricing/reimbursement reformmedium
Astria's product candidates require FDA marketing approval (a lengthy BLA/NDA review, complicated by its drug-device combination and PK bridging requirements), and Medicare/government reimbursement reductions could reduce future product pricing and revenue.
“Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors.”
SEC filing →As of 2025
The hidden graph
Who it depends on, and who depends on it.
Relationships surfaced from filings, including ones disclosed by the other side, which is how the non-obvious ones come to light.
Its suppliers
Ichnos Sciences
“The Company concluded that the Ichnos License Agreement was not the acquisition of a business, as substantially all of the fair value of the gross assets acquired was concentrated in a single identifiable asset “ISB 830-X8”, referred to by the Company as the STAR-0310 candidate.”
Cited →
In the MyPRIA app, this is checked against the companies you actually own.
← World Watch